打开APP

诺华公司未能说英国NICE批准其药物Afinitor

  1. Afinitor
  2. NICE
  3. 英国市场
  4. 诺华公司

来源:生物谷 2013-09-06 09:53

2013年9月5日讯 /生物谷BIOON/ --为了赢得英国成本效益评估部门The National Institute for Health and Care Excellence (NICE)的认可,公司对其昂贵的抗癌药物Afinitor进行了一定的折扣。如今看来效果并不明显。NICE拒绝其作为HER2阴性乳腺癌药物。

2013年9月5日讯 /生物谷BIOON/ --为了赢得英国成本效益评估部门The National Institute for Health and Care Excellence (NICE)的认可,公司对其昂贵的抗癌药物Afinitor进行了一定的折扣。如今看来效果并不明显。NICE拒绝其作为HER2阴性乳腺癌药物。

NICE表示,Afinitor高昂的价格使其很难成为一种惠及大部分消费者的药物。虽然这种药物的确能延长患者的生存时间,但是这种效果并不完全确定。基于这些考虑,NICE最终做出了如上决定。此前Afinitor在其治疗肝癌的申请中也遭受了挫折。(生物谷Bioon.com)

详细英文报道:

To win over U.K. cost-effectiveness gatekeepers, Novartis ($NVS) cut Afinitor's price. Unfortunately for the Swiss drugmaker, it didn't work. The National Institute for Health and Care Excellence (NICE) still turned down a new use for the drug in HER2-negative breast cancer.

There's no doubt that Afinitor bears a rich sticker price. A 30-pill pack of 10 mg tablets costs ?2,970 ($4,600), NICE says. How much Novartis knocked off the treatment cost isn't public; NICE's discount offers--or patient access schemes, as the agency calls them--are confidential. Whatever it was, it wasn't enough to make Afinitor worth it for women with advanced HER2-negative, hormone-receptor-positive cancer, NICE chief Sir Andrew Dillon said in a statement.

NICE's independent appraisal committee acknowledged that Afinitor could delay cancer growth by about four months, but cited "uncertainties" about its ability to prolong patients' lives, compared with the standard treatment Aromasin (exemestane). "Using the evidence that was available, the committee concluded that everolimus is not a cost-effective option for the NHS," Dillon said.

Afinitor's rejection is just the latest for breast cancer treatments at NICE. Roche's ($RHHBY) Avastin, Eisai's Halaven and GlaxoSmithKline's ($GSK) Tyverb have all had their turn. With breast cancer as the U.K.'s most common cancer--and other countries watching NICE decisions closely--those decisions have dashed hopes for drugmakers struggling to replace patent-cliff losses.

Novartis itself has been looking for a big boost from breast cancer for Afinitor. Analysts figure the indication could add $1.5 billion to the drug's global peak sales. Its other plans for Afinitor also took a hit recently, with the drug's failure in a liver cancer trial.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->